ABIVAX Société Anonyme ABVX
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -37.03%
- 1 year
- -17.10%
- Open
- 87.32
- Prev close
- 86.59
- Mkt cap
- 7.43B
- Vol
- 730.32K
- Avg vol
- 1.09M
- EPS
- -6.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 83.63
- High
- 87.50
- Forward P/E
- -22.14
- Beta
- -0.34
- Short ratio
- 5.08
- Inst. own
- 72.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 21, 2026
- 50-d avg
- 100.14
- 200-d avg
- 114.10
- 1y target
- 163.58
5D chart
Signals (125)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 10:30 AM | 13 hours ago |
| SMA: Bearish | Nov 2, 10:30 AM | 13 hours ago |
| MACD: Sell Signal | Nov 2, 10:30 AM | 13 hours ago |
| MACD: Buy Signal | Nov 2, 10:25 AM | 13 hours ago |
| SMA: Bullish | Nov 2, 10:20 AM | 13 hours ago |
| SMA: Bullish | Nov 2, 10:20 AM | 13 hours ago |
| SMA: Bearish | Nov 2, 10:00 AM | 13 hours ago |
| SMA: Bearish | Nov 2, 10:00 AM | 13 hours ago |
| SMA: Bullish | Nov 2, 9:55 AM | 14 hours ago |
| SMA: Bullish | Nov 2, 9:55 AM | 14 hours ago |
| SMA: Bearish | Nov 2, 9:50 AM | 14 hours ago |
| MACD: Sell Signal | Nov 2, 9:50 AM | 14 hours ago |
| SMA: Bullish | Nov 2, 9:45 AM | 14 hours ago |
| SMA: Bearish | Nov 2, 9:40 AM | 14 hours ago |
| SMA: Bearish | Nov 2, 9:40 AM | 14 hours ago |
| SMA: Bullish | Oct 30, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 3 days ago |
Newest 20 of 125.
Discussion (3)
Sign in to join the discussion
Tim F ABVX 5 months ago #1What a shit show that was. Beat the living hell outta it and then buy it back hand over fist…what?
Tim F ABVX 9 months ago #2Somebody wants this pharma company
Abvx/Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
Terry Chrisomalis
Summary
Abivax SA (ABVX) retains a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis.
Upcoming catalysts include 44-week maintenance data from ABTECT trials in Q2 2026 and potential NDA/MAA filings in H2 2026, contingent on positive results.
Obefazimod's oral dosing, favorable safety, and novel miR-124 mechanism position ABVX to penetrate 2nd/3rd-line UC therapy, move to 1st-line and expand into Crohn's disease.
Recent $700M+ capital raise extends cash runway into Q4 2027, supporting ongoing pivotal trials and strategic expansion opportunitie